Measuring success in clinical gene therapy research

Molecular Medicine Today

Volumn 2, Issue 6, 1996, Pages 234-236

  Culver, Kenneth W ^a  

^a Oncor Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL; GENE THERAPY; GENE TRANSFER; HUMAN; RESEARCH; REVIEW;

CLINICAL TRIALS; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; RESEARCH;

EID: 0030159956     PISSN: 13574310     EISSN: None     Source Type: Journal    
DOI: 10.1016/1357-4310(96)88803-4     Document Type: Article

References (11)

1. Friedman, T. (1996) Human gene therapy - an immature genie but certainly out of the bottle, Nat. Med. 2, 144-147
2. Touchette, N. (1996) Gene therapy: not ready for prime time, Nat. Med. 2, 7-8
3. Culver, K.W. (1996) Gene Therapy: a Primer for Physicians, Mary Ann Liebert
4. Rogers, S. (1976) Reflections on issues posed by recombinant DNA molecule technology. II, Ann. New York Acad. Sci. 265, 66-70
5. Cline, M.J. (1985) Perspectives for gene therapy: inserting new genetic information into mammalian cells by physical techniques and viral vectors, Pharmacol. Ther. 29, 69-92
6. Rosenberg, S.A. et al. (1990) Gene transfer into humans - immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. New Engl. J. Med. 323, 570-578
7. Blaese, R.M., Culver, K.W. and Anderson, W.F. (1990) The ADA human gene therapy clinical protocol, Hum. Gene Ther. 1, 331-362
8. Planck, M. (1936) The Philosophy of Physics, C. Allen & Unwin
9. Wahl, A.F. et al. (1996) Loss of normal p53 function confers sensitization to taxol by increasing G2/M arrest and apoptosis, Nat Med. 2, 72-79
10. Fick, J. et al. (1995) The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro, Proc. Natl Acad. Sci. USA 92, 11071-11075
11. Planck, M. (1932) Where is science going? W.W. Norton & Co.